TNF-alpha, IL-6, IL-10 and fatty acids in rheumatoid arthritis patients receiving cDMARD and bDMARD therapy
dc.authorid | Ozkan, Huseyin/0000-0001-5753-8985 | |
dc.authorid | Camdeviren, Baran/0000-0003-1508-7869 | |
dc.authorid | Kacmaz, Filiz/0000-0002-7166-8265 | |
dc.contributor.author | Dogan, Serdar | |
dc.contributor.author | Kimyon, Gezmis | |
dc.contributor.author | Ozkan, Huseyin | |
dc.contributor.author | Kacmaz, Filiz | |
dc.contributor.author | Camdeviren, Baran | |
dc.contributor.author | Karaaslan, Irem | |
dc.date.accessioned | 2024-09-18T20:04:21Z | |
dc.date.available | 2024-09-18T20:04:21Z | |
dc.date.issued | 2022 | |
dc.department | Hatay Mustafa Kemal Üniversitesi | en_US |
dc.description.abstract | Objective The present study aimed to examine the effects of cDMARD and bDMARD therapy on both gene expressions and protein levels of TNF-alpha, IL-6, IL-10 and fatty acid levels in patients with RA. Method Plasma TNF-alpha, IL-6, and IL-10 levels were examined by the ELISA method, while TNF-alpha, IL-6, and IL-10 gene expression levels were examined by RT-qPCR, and fatty acid levels were examined by GC/MS. Results IL-10 gene expression levels significantly increased in RA patients receiving cDMARD treatment compared to those of the control group. Also, eicosadienoic acid, myristoleic acid and capric acid levels were significantly lower in the patient groups compared to those in the control group. Conclusion The drugs used in the treatment of RA had no effect on the fatty acid levels whereas had effects on the mRNA and protein levels of the target cytokines. | en_US |
dc.identifier.doi | 10.1007/s10067-022-06180-5 | |
dc.identifier.endpage | 2349 | en_US |
dc.identifier.issn | 0770-3198 | |
dc.identifier.issn | 1434-9949 | |
dc.identifier.issue | 8 | en_US |
dc.identifier.pmid | 35467309 | en_US |
dc.identifier.scopus | 2-s2.0-85128856426 | en_US |
dc.identifier.scopusquality | Q1 | en_US |
dc.identifier.startpage | 2341 | en_US |
dc.identifier.uri | https://doi.org/10.1007/s10067-022-06180-5 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12483/8096 | |
dc.identifier.volume | 41 | en_US |
dc.identifier.wos | WOS:000787112600001 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer London Ltd | en_US |
dc.relation.ispartof | Clinical Rheumatology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | bDMARD | en_US |
dc.subject | cDMARD | en_US |
dc.subject | Free fatty acid | en_US |
dc.subject | IL-10 | en_US |
dc.subject | Rheumatoid arthritis | en_US |
dc.title | TNF-alpha, IL-6, IL-10 and fatty acids in rheumatoid arthritis patients receiving cDMARD and bDMARD therapy | en_US |
dc.type | Article | en_US |
Dosyalar
Orijinal paket
1 - 1 / 1